A role of pancreatic stellate cells in islet fibrosis and β-cell dysfunction in type 2 diabetes mellitus

2017 ◽  
Vol 485 (2) ◽  
pp. 328-334 ◽  
Author(s):  
Esder Lee ◽  
Gyeong Ryul Ryu ◽  
Seung-Hyun Ko ◽  
Yu-Bae Ahn ◽  
Ki-Ho Song
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Stellate Cells ◽  
Pancreatic Stellate Cells ◽  
Β Cell ◽  
Cell Dysfunction

scholarly journals An Immediate and Long-Term Complication of COVID-19 May Be Type 2 Diabetes Mellitus: The Central Role of β-Cell Dysfunction, Apoptosis and Exploration of Possible Mechanisms

Cells ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 2475
Author(s):  
Melvin R. Hayden
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cell Injury ◽  
Light And Electron Microscopy ◽  
Β Cell ◽  
Cell Dysfunction

The novel coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was declared a pandemic by the WHO on 19 March 2020. This pandemic is associated with markedly elevated blood glucose levels and a remarkable degree of insulin resistance, which suggests pancreatic islet β-cell dysfunction or apoptosis and insulin’s inability to dispose of glucose into cellular tissues. Diabetes is known to be one of the top pre-existing co-morbidities associated with the severity of COVID-19 along with hypertension, cardiocerebrovascular disease, advanced age, male gender, and recently obesity. This review focuses on how COVID-19 may be responsible for the accelerated development of type 2 diabetes mellitus (T2DM) as one of its acute and suspected long-term complications. These observations implicate an active role of metabolic syndrome, systemic and tissue islet renin–angiotensin–aldosterone system, redox stress, inflammation, islet fibrosis, amyloid deposition along with β-cell dysfunction and apoptosis in those who develop T2DM. Utilizing light and electron microscopy in preclinical rodent models and human islets may help to better understand how COVID-19 accelerates islet and β-cell injury and remodeling to result in the long-term complications of T2DM.

scholarly journals The Role of CD36 in Type 2 Diabetes Mellitus: β-Cell Dysfunction and Beyond

2020 ◽  
Vol 44 (2) ◽  
pp. 222 ◽  
Author(s):  
Jun Sung Moon ◽  
Udayakumar Karunakaran ◽  
Elumalai Suma ◽  
Seung Min Chung ◽  
Kyu Chang Won
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Β Cell ◽  
Cell Dysfunction

Hyperglycemia and hyperinsulinemia have additive effects on activation and proliferation of pancreatic stellate cells: Possible explanation of islet-specific fibrosis in type 2 diabetes mellitus

2007 ◽  
Vol 101 (3) ◽  
pp. 665-675 ◽  
Author(s):  
Oak-Kee Hong ◽  
Seung-Hwan Lee ◽  
Marie Rhee ◽  
Seung-Hyun Ko ◽  
Jae-Hyoung Cho ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Stellate Cells ◽  
Pancreatic Stellate Cells ◽  
Additive Effects

New emerging roles of the novel hepatokine SERPINB1 in type 2 diabetes mellitus: crosstalk with β-cell dysfunction and dyslipidemia

2020 ◽  
Author(s):  
Mohamed Mostafa Kamal ◽  
Aya Adel ◽  
Ghada Hussein Sayed ◽  
Shadia Ragab ◽  
Dina Hamada Kassem
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
The Novel ◽  
Β Cell ◽  
Cell Dysfunction

scholarly journals Risk Factors for Type 2 Diabetes Mellitus Preceded by β-Cell Dysfunction, Insulin Resistance, or Both in Older Adults

2013 ◽  
Vol 177 (12) ◽  
pp. 1418-1429 ◽  
Author(s):  
Fumiaki Imamura ◽  
Kenneth J. Mukamal ◽  
James B. Meigs ◽  
José A. Luchsinger ◽  
Joachim H. Ix ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Older Adults ◽  
Type 2 Diabetes Mellitus ◽  
Β Cell ◽  
Cell Dysfunction

scholarly journals Role of conventional oral antidiabetic drugs in management of type 2 diabetes mellitus

2017 ◽  
Vol 5 (3) ◽  
pp. 749 ◽  
Author(s):  
Vaishali Thakare ◽  
Shrikrishna S. Shende ◽  
Prashant A. Shirure ◽  
Onkar C. Swami
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
American Diabetes Association ◽  
Antidiabetic Drugs ◽  
Oral Antidiabetic Drugs ◽  
Cell Dysfunction ◽  
Oral Antidiabetic

Type 2 diabetes mellitus (T2DM) is caused by insulin resistance and characterized by progressive pancreatic β-cell dysfunction. Recent innovative treatment approaches target the multiple pathophysiological defects present in type 2 diabetes. The targets for glycemic control as set by the American Diabetes Association (HbA1C<7%) and the American Association of Clinical Endocrinologists (HbA1C<6.5%) sometimes appear daunting and unattainable. It is therefore of the utmost importance to have an excellent understanding of the mechanism of action of these drugs in order to optimize patient therapy. Here, we present a corresponding discussion of all the available oral antidiabetic drugs according to the different classes, their mechanisms of action and pharmacological profiles.

Sign in / Sign up

Export Citation Format

Share Document